1. Evaluation of inosin-5′-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
- Author
-
Maiguma, T., Yosida, T., Otsubo, K., Okabe, Y., Sugitani, A., Tanaka, M., Oishi, R., and Teshima, D.
- Subjects
DEHYDROGENASES ,THERAPEUTICS ,TACROLIMUS ,DRUG analysis ,IMMUNOSUPPRESSIVE agents - Abstract
Objectives: The aim of this study was to identify a target range for inosin-5′-monophosphate dehydrogenase (IMPDH) activity in maintenance therapy with tacrolimus (TCL), and to apply the measurement of IMPDH activity to the therapeutic drug monitoring for mycophenolate mofetil (MMF). Methods: Eleven patients with renal transplants and 10 healthy volunteers were investigated. All patients were treated with a combination of TCL, steroid and MMF for 2 months after transplantation, and were in stable and good condition. IMPDH activity was determined indirectly by measuring xanthosine 5′-monophophate in cell lysates supplemented with IMP and β-nicotine adenine dinucleotide using an high-performance liquid chromatography (HPLC) method. Results: The within-run reproducibility of the assay was excellent, with relative standard deviation (RSD) values of 0·41–4·08%. The mean differences between the spiked concentrations of xanthosine 5′-monophophate and their real values (mean relative errors; MREs) were within a range of 2·66–8·89%, showing good accuracy. The interday RSD values were 1·51–6·12% and MREs ranged from 2·10% to 8·89%. Cell lysates showed a 5–6 nmol/L IC
50 mycophenolic acid (MPA) concentration. TCL, cyclosporine and prednisolone did not affect IMPDH activity. The peak MPA concentration was achieved at 1 h after dosing. IMPDH activity decreased to 75% and 67% at 1 and 2 h after dosing respectively. Therefore, the inhibition rates of MPA against IMPDH activity may be adequate at 25–40% in TCL maintenance therapy. Conclusion: Inosin-5′-monophosphate dehydrogenase activity in cell lysates could be reliably determined by HPLC. A 25–40% inhibition of IMPDH activity may be an appropriate range for preventing rejection with MPF but this requires further validation using larger studies with harder outcomes such as rejection episodes. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF